## edexcel

Mark Scheme (Results)
Summer 2015

Pearson Edexcel International
Advanced Level
in Biology (WBI01) Paper 01 -
Lifestyle, Transport, Genes and Health

## Edexcel and BTEC Qualifications

Edexcel and BTEC qualifications are awarded by Pearson, the UK's largest awarding body. We provide a wide range of qualifications including academic, vocational, occupational and specific programmes for employers. For further information visit our qualifications websites at www.edexcel.com or www.btec.co.uk. Alternatively, you can get in touch with us using the details on our contact us page at www.edexcel.com/contactus.

Pearson: helping people progress, everywhere
Pearson aspires to be the world's leading learning company. Our aim is to help everyone progress in their lives through education. We believe in every kind of learning, for all kinds of people, wherever they are in the world. We've been involved in education for over 150 years, and by working across 70 countries, in 100 languages, we have built an international reputation for our commitment to high standards and raising achievement through innovation in education. Find out more about how we can help you and your students at: www.pearson.com/uk

Summer 2015
Publications Code IA040928*
All the material in this publication is copyright
© Pearson Education Ltd 2015

- All candidates must receive the same treatment. Examiners must mark the first candidate in exactly the same way as they mark the last.
- Mark schemes should be applied positively. Candidates must be rewarded for what they have shown they can do rather than penalised for omissions.
- Examiners should mark according to the mark scheme not according to their perception of where the grade boundaries may lie.
- There is no ceiling on achievement. All marks on the mark scheme should be used appropriately.
- All the marks on the mark scheme are designed to be awarded. Examiners should always award full marks if deserved, i.e. if the answer matches the mark scheme. Examiners should also be prepared to award zero marks if the candidate's response is not worthy of credit according to the mark scheme.
- Where some judgement is required, mark schemes will provide the principles by which marks will be awarded and exemplification may be limited.
- When examiners are in doubt regarding the application of the mark scheme to a candidate's response, the team leader must be consulted.
- Crossed out work should be marked UNLESS the candidate has replaced it with an alternative response.

| Question <br> Number | Answer | Mark |
| :--- | :--- | ---: |
| $1(\mathrm{a})(\mathrm{i})$ | B platelets | $(1)$ |


| Question <br> Number | Answer | Mark |
| :--- | :--- | ---: |
| 1(a)(ii) | D protein | (1) |


| Question <br> Number | Answer | Mark |
| :---: | :--- | :---: |
| 1(a)(iii) | C prothrombin into thrombin | $(1)$ |


| Question Number | Answer | Additional Guidance | Mark |
| :---: | :---: | :---: | :---: |
| 1(b)(i) | 1. the clotting time only changes at heparin concentrations above 0.5(au) ; <br> 2. there is a decrease in clotting time up to $2(\mathrm{au})$; <br> 3. there is an increase in clotting time \{ above 2(au)/from 3 to 4(au) \} ; <br> 4. comparisons between initial and final value 156.7 s increase / $6.2 \times$ increase / 520\% increase OR between initial and 2 au value 2.8 s decrease / $9.3 \%$ decrease ; | 1. ACCEPT no change between 0 and $0.5(\mathrm{au}) / 0.5(\mathrm{au})$ has no effect <br> 2. ACCEPT shortest clotting time is at $2(a u)$ | (3) |


| Question <br> Number | Answer | Additional Guidance | Mark |
| :--- | :---: | :---: | :---: |
| 1 (b)(ii) | clotting is slower / inhibited / reduced / stopped; | ACCEPT clotting time is <br> increased / longer | $(1)$ |


| Question <br> Number | Answer | Additional Guidance | Mark |
| :---: | :---: | :--- | :---: |
| 1(b)(iii) | risk of excessive blood loss; | ACCEPT bleeding in the brain / <br> bleeding to death / <br> internal bleeding / |  |
|  |  | ACCEPT thrombocytopenia | (1) |


| Question <br> Number | Answer | Additional Guidance | Mark |
| :--- | :--- | :--- | :--- |
| 2(a) | 1. reference to consisting of $\mathrm{C}, \mathrm{H}$ and O/eq; | ACCEPT correct general formula <br> $\left(\mathrm{CH}_{2} \mathrm{O}\right)$ n for both MP1 and MP3 <br> e.g. $\mathrm{C}_{6} \mathrm{H}_{12} \mathrm{O}_{6}$ gains both marks |  |
|  | 2. no glycosidic bonds / one sugar unit ; | 2. ACCEPT monomer / single <br> ring structure / simple sugar <br> IGNORE one sugar / one <br> molecule |  |
|  | 3. idea of ratio of C:H:O is 1:2:1; |  | (2) |


| Question <br> Number | Answer | Additional Guidance | Mark |
| :--- | :--- | :--- | :--- |
| 2(b) | 1. idea of different position of $\{\mathrm{H} / \mathrm{OH}\}$ on carbon 1; <br> 2. idea of different position of $\{\mathrm{H} / \mathrm{OH}\}$ on carbon 4; | ACCEPT C as equivalent to <br> carbon |  |


| Question <br> Number | Answer | Mark |
| :--- | :--- | ---: |
| $2(\mathrm{c})(\mathrm{i})$ | B lactose | $(1)$ |


| Question Number | Answer | Additional Guidance | Mark |
| :---: | :---: | :---: | :---: |
| 2(c)(ii) | 1. reference to glycosidic bond ; <br> 2. between (C) 1 and (C) 4 / eq ; <br> 3. by condensation (reaction) ; <br> 4. idea that water is lost ; | ACCEPT suitable annotated diagram for any Mark Points formation of 1, 4 glycosidic bond gains MP1 \& MP2 | (3) |


| Question <br> Number | Answer | Additional Guidance | Mark |
| :---: | :--- | :--- | :--- |
| 2(c)(iii) | 1. reference to enzymes being \{ specific \} ; <br> 2. due to shape of active site ; <br> 3. only allowing certain substrates to \{ bind / fit / form a <br> complex / eq \} ; <br> 4. glucose molecule and galactose molecule have different <br> shapes ; | 1. ACCEPT enzymes have <br> \{ specific \} substrates | 3. IGNORE reference to 'lock <br> and key' if unqualified |


| Question <br> Number | Answer |  |  | Additional Guidance |
| :--- | :--- | :--- | :--- | :--- | Mark


| Question Number | Answer | Additional Guidance | Mark |
| :---: | :---: | :---: | :---: |
| 3(a) | 1. (fibrous proteins) are \{ long / contain many amino acids \}; <br> 2. amino acid sequence is repetitive / eq ; <br> 3. idea of limited folding; <br> 4. polypeptides lie parallel to each other ; <br> 5. idea of bonds linking chains together ; | 3. ACCEPT \{ no / limited / eq \} tertiary structure I GNORE reference to 3D shape etc. <br> 4. ACCEPT parallel chains <br> 5. ACCEPT cross linked chains ACCEPT any named bond between chains |  |


| Question <br> Number | Answer | Additional Guidance | Mark |
| :--- | :--- | :--- | :--- |
| 3(b) | 1. mutation changes the sequence of bases in \{ DNA / gene \} ; <br> 2. this could result in a different amino acid ; <br> 3. resulting in different \{ bonding / folding \} ; <br> 4. changing the \{ shape / strength / eq \} of the protein ; | 2. ACCEPT different primary <br> structure |  |
| 4. ACCEPT references to <br> changing secondary / tertiary <br> structures |  |  |  |


| Question <br> Number | Answer | Additional Guidance | Mark |
| :--- | :--- | :--- | :---: |
| 3(c) | 1. (blood) pressure in the arteries is high; <br> 2. artery (walls) contain collagen; <br> 3. collagen provides strength (to the artery wall); | IGNORE references to elasticity <br> ACCEPT converse statements |  |


| Question <br> Number | Answer | Additional Guidance | Mark |
| :--- | :--- | :--- | :--- |
| 3(d) | 1. parents each contain one recessive allele; <br> 2. indication that the gametes could contain either the <br> dominant or the recessive allele; <br> 3. credit an indication of the possible genotypes from <br> fertilisation e.g. Punnet square; <br> 4. indication of the genotype that results in EDS; <br> 5. indication that probability is 0.25 / eq ; <br> [award points from a clear genetic diagram] | NOT simply a reference to <br> parents being heterozygous or <br> carriers |  |


| Question Number | Answer | Additional Guidance | Mark |
| :---: | :---: | :---: | :---: |
| 4(a) | 1. (in general) an increase in diastolic blood pressure increases death rate ; <br> 2. at higher systolic pressure the effect of diastolic pressure is \{ variable / irregular \}; <br> 3. an increase in systolic blood pressure increases death rate ; <br> 4. a high systolic blood pressure has a greater influence on death rate than diastolic blood pressure ; <br> 5. greatest death rate is associated with systolic pressure $>21.2$ and diastolic pressure <9.3; | ACCEPT 'risk' in place of death rate <br> ACCEPT converse arguments for MP1, MP3 and MP4 <br> 5. ACCEPT greatest death rate is associated with highest systolic and lowest diastolic pressure | (3) |


| Question <br> Number | Answer | Additional Guidance | Mark |
| :--- | :--- | :--- | :--- |
| 4(b) | 1. high blood pressure can cause damage to the endothelial <br> (lining of arteries); <br> 2. leads to \{ inflammatory response / accumulation of white <br> blood cells \} ; <br> 3. reference to formation of \{ plaque / atheroma / <br> atherosclerosis \} ; | 2. IGNORE immune response |  |
| 4. lumen is \{ restricted / narrowed \} ; |  |  |  |
| 5. resulting in cells being deprived of \{ oxygen / nutrient \} ; | 5. ACCEPT reduced blood supply <br> to cells | 4. ACCEPT 'blocked' <br> IGNORE artery narrows |  |


| Question <br> Number | Answer | Additional Guidance | Mark |
| :--- | :--- | :--- | :--- |
| 4(c) | Any two from: <br> 1. age <br> 2. genetics <br> 3. smoking / tobacco products <br> 4. lack of exercise <br> 5. high \{ salt / sodium \} consumption <br> 6. stress / adrenalin <br> 7. being overweight / obese | 2. ACCEPT race / gender |  |


| Question <br> Number | Answer | Mark |
| :--- | :--- | ---: |
| $4(\mathrm{~d})$ | B antihypertensive | $(1)$ |


| Question <br> Number | Answer | Additional Guidance | Mark |
| :--- | :--- | :--- | :--- |
| $5(\mathrm{a})$ | 1. catalase is a catalyst ; <br> 2. reference to \{ lowering / eq \} activation energy ; <br> 3. without being used up in the reaction / eq ; <br> 4. idea that once reaction is complete, the enzyme <br> detaches from products ; | 1. IGNORE catalase is an <br> enzyme |  |
| 5. and can then bind to another \{ substrate / hydrogen <br> peroxide\} ; | 3. ALLOW without being <br> changed |  |  |


| Question <br> Number | Answer | Mark |
| :--- | :--- | ---: |
| $5(\mathrm{~b})(\mathrm{i})$ | B one | $(1)$ |



| Question Number | Answer | Additional Guidance | Mark |
| :---: | :---: | :---: | :---: |
| 6(a) | 1. DNA replication produces DNA and transcription produces (m)RNA ; <br> 2. in DNA replication thymine $(T)$ is used but in transcription uracil ( U ) is used (as complementary base to adenine (A)) <br> 3. DNA has deoxyribose and (m)RNA has ribose ; <br> 4. DNA is double stranded and (m)RNA is single stranded; <br> 5. DNA is helical and (m)RNA is straight / eq ; | comparisons are required for each marking point <br> 2. ACCEPT new DNA strand will be TCGCGAACG and RNA will be UCGCGAACG | (3) |


| Question Number | Answer | Additional Guidance | Mark |
| :---: | :---: | :---: | :---: |
| * 6 (b) | (QWC - Spelling of technical terms must be correct and the answer must be organised in a logical sequence) <br> 1. idea that a mRNA copy is made ; <br> 2. sequence of RNA is $U C G C G A A C G$; <br> 3. mRNA leaves the nucleus ; <br> 4. idea of association of mRNA with ribosome ; <br> 5. each tRNA attaches to a specific amino acid / eq ; <br> 6. tRNA transfers the amino acid (to the ribosome / mRNA) / eq ; <br> 7. idea of complementary base pairing between tRNA and mRNA ; <br> 8. reference to peptide bonds forming between amino acids ; | QWC emphasis answer must be in a logical sequence <br> 3. I GNORE mRNA enters cytoplasm <br> 7. ACCEPT anticodon codon interaction |  |


| Question Number | Answer | Additional Guidance | Mark |
| :---: | :---: | :---: | :---: |
| 7 (a) | 1. add up resting heart rate and heart rate after drink ; <br> 2. divide each total by three ; <br> 3. subtract resting heart rate from heart rate after drink; <br> OR <br> 4. subtract each resting heart rate from heart rate after drink ; <br> 5. add up the differences ; <br> 6. divide by three; <br> [award mark points from clear calculation] | 1. \& 2. ALLOW 'calculate the mean for resting and after drinking heart rates' for one mark if MP1 and 2 not awarded <br> 2. \& 6. ACCEPT divide by the number of students <br> 5. \& 6. ALLOW 'calculate the mean for difference in heart rates' for one mark if MP5 and 6 not awarded <br> ALLOW full marks for correct explanation / calculations if student 2 identified as anomalous and excluded <br> I GNORE additional manipulations e.g. calculating a percentage change |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  | (3) |


| Question <br> Number | Answer | Additional Guidance | Mark |
| :--- | :--- | :--- | :---: |
| 7 (b) | 1. use more students ; | IGNORE reference to standard <br> deviation |  |
|  | 2. repeat the investigation on each student; |  | (2) |


| Question <br> Number | Answer | Additional Guidance | Mark |
| :--- | :--- | :--- | :--- |
| 7(c) | 1. use a \{ caffeine-free drink / caffeine solution \}; <br> 2. to rule out the effects of other components of the drink ; <br> OR use a placebo / do a blind trial / eq ; <br> 4. to rule out the placebo effect / eq ; <br> OR <br> 5. use drinks with different concentrations of caffeine ; <br> 6. to establish correlation between concentration and heart <br> rate ; | IGNORE unqualified <br> references to controlling <br> other variables or control of <br> variables other than <br> components of the drink |  |


| Question <br> Number | Answer | Mark |
| :--- | :---: | :---: |
| $8(\mathrm{a})(\mathrm{i})$ | A large surface area and high concentration gradient | $(1)$ |


| Question <br> Number | Answer | Mark |
| :--- | :--- | :---: |
| 8(a)(ii) | B diffusion | $(1)$ |


| Question <br> Number | Answer | Additional Guidance | Mark |
| :--- | :--- | :--- | :---: |
| $8(\mathrm{~b})(\mathrm{i})$ | 1. PFR is greater in men than in women / eq ; <br> 2. PFR is greatest in men at the age of $35-38$ and in <br> women at age of $30-32 ;$ | 2. ACCEPT peak flow rate in <br> men occurs 5 years after peak <br> flow rate in women |  |
| 3. (on average) men have larger lungs than women ; <br> 4. men have more muscular chests (than women); |  | (3) |  |


| Question <br> Number | Answer | Additional Guidance | Mark |
| :---: | :--- | :--- | :--- |
| 8(b)(ii) | 1. similar shape / shape described; | description including: <br> initial value between $420-450$ <br> peak value between $470-500$ <br> end value between $340-370$ <br> 2. idea of line being higher (than for women of 175 cm ); |  |
|  |  | gains both marking points | (2) |


| Question Number | Answer | Additional Guidance | Mark |
| :---: | :---: | :---: | :---: |
| 8(c) | 1. reference to a \{ defective / mutated / eq \} CFTR gene ; <br> 2. idea that the CFTR \{ channel / protein \} cannot function properly ; <br> 3. as a result chloride ions \{ build up inside the cells / are not exported from the cells / eq \} ; <br> 4. \{ thick / thicker / sticky / eq \} mucus ; <br> 5. in the $\{$ airways / bronchi / bronchioles / eq \} ; <br> 6. this \{ mucus \} reduces flow of air / PFR ; | 2. ALLOW does not allow chloride ions to pass through <br> 4. I GNORE more mucus produced / present <br> 5. I GNORE in the lungs / in the alveoli <br> 6. DO NOT ACCEPT reference to reduced gas exchange causing reduced air flow I GNORE reduces ability to breath | (4) |

Pearson Education Limited. Registered company number 872828

